Heidelberg Pharma AG (XTER:HPHA) Total Liabilities : €16.55 Mil (As of Feb. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Heidelberg Pharma AG Total Liabilities?

Heidelberg Pharma AG's Total Liabilities for the quarter that ended in Feb. 2024 was €16.55 Mil.

Heidelberg Pharma AG's quarterly Total Liabilities declined from Aug. 2023 (€22.84 Mil) to Nov. 2023 (€21.01 Mil) and declined from Nov. 2023 (€21.01 Mil) to Feb. 2024 (€16.55 Mil).

Heidelberg Pharma AG's annual Total Liabilities increased from Nov. 2021 (€15.03 Mil) to Nov. 2022 (€33.94 Mil) but then declined from Nov. 2022 (€33.94 Mil) to Nov. 2023 (€21.01 Mil).

Heidelberg Pharma AG Total Liabilities Historical Data

The historical data trend for Heidelberg Pharma AG's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heidelberg Pharma AG Total Liabilities Chart

Heidelberg Pharma AG Annual Data

Trend

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Nov23

Total Liabilities

Get a 7-Day Free Trial

6.70

6.73

15.03

33.94

21.01

Heidelberg Pharma AG Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Total Liabilities	Get a 7-Day Free Trial															26.31	27.07	22.84	21.01	16.55

Heidelberg Pharma AG Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Heidelberg Pharma AG's Total Liabilities for the fiscal year that ended in Nov. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	19.775	+	(0.07	+	1.168
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	21.01

Total Liabilities	=	Total Assets (A: Nov. 2023 )	-	Total Equity (A: Nov. 2023 )
	=	70.353	-	49.34
	=	21.01

Heidelberg Pharma AG's Total Liabilities for the quarter that ended in Feb. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	16.483	+	(0.07	+	-0.0010000000000009
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	16.55

Total Liabilities	=	Total Assets (Q: Feb. 2024 )	-	Total Equity (Q: Feb. 2024 )
	=	61.666	-	45.114
	=	16.55

Heidelberg Pharma AG Total Liabilities Related Terms

Thank you for viewing the detailed overview of Heidelberg Pharma AG's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Heidelberg Pharma AG (XTER:HPHA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

HPHA:Germany HPHA:Germany HPHA:Germany

Address

Gregor-Mendel-Street 22, Ladenburg, DEU, 68526

Website

https://www.heidelberg-pharma.com

Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.

Executives

Prof. Dr. Andreas Pahl

Board of Directors

Heidelberg Pharma AG (XTER:HPHA) Headlines

No Headlines